The global wearable injectors market is expected to grow significantly over the forecast period. It is estimated that the global wearable injectors market is expected to register a CAGR of ~ 15.2% during the forecast period from 2018 to 2023. Wearable Injectors are medical devices designed to dispense large doses of the drug. Wearable Injectors are user-friendly, convenient and they lessen the need for multiple painful injections.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6491

Numerous factors such as growing demand of convenient methods of drug administration, rising prevalence of chronic diseases such as diabetes, technological advancements and design development in wearable injectors are expected to drive the growth of the market. For instance, in July 2016, Amgen received US Food and Drug Administration (FDA) approval for its on-body wearable injector, Repatha (evolocumab) Pushtronex system, a human monoclonal antibody injector.

Moreover, favorable healthcare investments by government and the rising demand for minimally invasive devices boosts the growth of the market. However, stringent government regulation for product approval and the growing preference for traditional methods of drug delivery may hamper the market growth during the assessment period.

Segmentation

The global wearable injectors market has been segmented into type, usage, mechanism of action, therapeutic area, and end-user.

The market, on the basis of type, has been segmented into on-body wearable injectors, off-body wearable injectors, and hand-held wearable injectors.

The market, by usage, has been segmented into disposable and semi-reusable.

The market, by mechanism of action, has been segmented into spring based, motor driven, rotary pump, expanding battery, pressurized gas, and collapsible reservoir.

The market, by therapeutic area, has been segmented into oncology, infectious diseases, cardiovascular diseases, autoimmune diseases, diabetes, and others.

The market, by end-user, has been segmented into hospitals, clinics, homecare, ambulatory surgery centers, others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The wearable injectors market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European wearable injectors market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The wearable injectors market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The wearable injectors market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players

West Pharmaceutical Services, Inc., Valeritas, Inc., Eli Lilly and Company, YPSOMED, Amgen Inc., Becton, Dickinson and Company (BD), CeQur SA, SteadyMed Therapeutics, Inc., BioSpace, Enable Injections, and Sensile Medical AG are some of the key players in the global wearable injectors market.

Regional Market Summary

Geographically, the Americas is anticipated to dominate the global wearable injectors market owing to a well-developed healthcare sector, rising prevalence of autoimmune and chronic disease and growing healthcare expenditure. According to a report published by American Autoimmune Related Diseases Association (AARDA) in April 2017, in the US approximately 50 million people i.e. nearly 20% population suffer from autoimmune diseases. Additionally, government funding in this region contributes to the growth of the market.

Europe is expected to hold the second largest position in the global wearable injectors market. The market growth in this region is attributed to the growing prevalence of chronic diseases, the availability of funds for research, and increasing healthcare expenditure. According to a report published by the NSD Alliance in July 2017, 1/3rd of the European population above the age of 15 years suffer from a chronic disease.

Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, rising prevalence of chronic diseases like diabetes, cardiovascular diseases and increasing government funding for the healthcare sector. According to a study published in the Asian Pacific Journal of Tropical Biomedicine journal in 2014, it was estimated that about 150 million diabetic patients reside within the region, out of which more than 95% have type 2 diabetes mellitus.

On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/wearable-injectors-market-6491